论文部分内容阅读
本文就瑞卡南(recainam,REC)短期治疗复杂性室性心律失常的疗效和安全性,进行了多种剂量的对照研究。方法①单盲试验期:11例慢性频发性室早病人,研究前停用所有抗心律失常药至少4个半衰期。病人先后口服REC 100、300和500mg,每8小时1次,各服用3天。②双盲、安慰剂、对照、交叉试验期:在单盲试验期对REC有效且能耐受的病人参加本期试验。病人随机口服REC(在单盲试验期的各有效剂量)或安慰剂1周,接着每个病人
In this paper, we conducted a multi-dose controlled study on the short-term efficacy and safety of recainam (REC) in the treatment of complex ventricular arrhythmias. Methods ① single-blind trial period: 11 cases of chronic ventricular premature patients, before the study discontinued all anti-arrhythmic drugs at least 4 half-lives. Patients have oral REC 100,300 and 500mg, once every 8 hours, each taking 3 days. ② double-blind, placebo, control, crossover trial period: In the single-blind trial of REC effective and tolerable patients to participate in the current trial. Patients were randomized to receive REC (each effective dose in a single blinded trial) or placebo for 1 week followed by each patient